DavidBenjaminMD

PubMed

• The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations.
  Jonathan Krell, Jeremy Warner, Mark P Lythgoe, Matthew J Hadfield, David J Benjamin> ;Trends in Cancer. 2024 Apr 6
• Cost effectiveness of immunotherapy combination therapies for endometrial cancer.
  David J Benjamin, William V Padula, Robert C Hsu> ;Gynecologic Oncology Reports. 2024 Apr 1
• The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
  David J Benjamin, Arash Rezazadeh Kalebasty, Vinay Prasad> ;European Urology Oncology. 2024 Mar 13
• Characterization of Thyroid Cancer among Hispanics in California, USA, from 2010 to 2020.
  Kai-Ya Tsai, Katherine Y Wojcik, Alice W Lee, Lihua Liu, Robert C Hsu, David J Benjamin, Krithika Chennapan, Jacob S Thomas, Jorge J Nieva> ;Cancers. 2024 Mar 8
• Diversifying editorial boards to mitigate the global burden of genitourinary cancers.
  David J Benjamin, Zhaohui Arter, Nataliya Mar, Arash Rezazadeh Kalebasty> ;Nature Reviews. Urology. 2024 Mar 1
• Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials.
  Alyson Haslam, Vinay Prasad, David J Benjamin> ;Cancer Medicine. 2024 Mar 1
• Supplement Use and Increased Risks of Cancer: Unveiling the Other Side of the Coin.
  Parnian Jabbari, Omid Yazdanpanah, David J Benjamin, Arash Rezazadeh Kalebasty> ;Cancers. 2024 Feb 22
• Evaluating regulatory consistency for international anti-PD-(L)1 clinical trials.
  Albert Q Wu, David J Benjamin, Vinay Prasad, Timothée Olivier> ;European Journal of Cancer. 2024 Apr 1
• Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020.
  Lythgoe, M., Kalebasty, A., Benjamin, D., Benjamin, D., Benjamin, D.> ;JCO Oncology Practice. 2024 Jan 16
• Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022.
  Rezazadeh Kalebasty, A., Benjamin, D.> ;Clinical Medicine Insights. Oncology. 2024 Jan 1
• A remnant never forgotten: the utility of circulating tumor DNA in treatment guidance of urachal cancer.
  Christopher Ryan Grant, David J Benjamin, Scott Cramer, Arash Rezazadeh Kalebasty> ;Therapeutic Advances in Medical Oncology. 2024 Jan 1
• A comparative study of spinal cord compression management in metastatic prostate cancer: Teaching versus non-teaching hospitals in the United States.
  Mahadevan, A., Omid Yazdanpanah, Aditya Mahadevan, Aditi Sharma, David J Benjamin, Arash Rezazadeh Kalebasty> ;Cancer Medicine. 2023 Dec 26
• 2 citations
  Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry.
  David J Benjamin, Anshu Shrestha, Dimitra Fellman, Rosemary D Cress, Mark P Lythgoe, Arash Rezazadeh Kalebasty> ;Prostate Cancer and Prostatic Diseases. 2023 Nov 14
• 1 citations
  Starting and stopping cancer drugs: The need for randomized trials.
  David J Benjamin, Vinay Prasad> ;Journal of Cancer Policy. 2023 Dec 1
• 1 citations
  Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry.
  David J Benjamin, Anshu Shrestha, Dimitra Fellman, Rosemary D Cress, Mark P Lythgoe, Arash Rezazadeh Kalebasty> ;Prostate Cancer and Prostatic Diseases. 2023 Oct 5
• 3 citations
  The FDA's latest draft guidance on accelerated approvals - one step forward, two steps back?
  David J Benjamin, Mark P Lythgoe> ;Nature Reviews. Clinical Oncology. 2023 Sep 1
• 1 citations
  Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapies.
  David J Benjamin, Arash Rezazadeh Kalebasty> ;Rare Tumors. 2023 Jan 1
• Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer.
  David J Benjamin, Vinay Prasad> ;The Oncologist. 2024 Feb 2
• Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
  David J Benjamin, Robert Hsu> ;Frontiers in Immunology. 2023 Jan 1
• 1 citations
  The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
  Robert Hsu, David J Benjamin, Misako Nagasaka> ;Cancers. 2023 Jul 10
• Prostate Cancer in Sexual Minorities: Epidemiology, Screening and Diagnosis, Treatment, and Quality of Life.
  Omid Yazdanpanah, David J Benjamin, Arash Rezazadeh Kalebasty> ;Cancers. 2023 May 8
• 2 citations
  Patient preferences in the treatment of genitourinary cancers.
  David J Benjamin, Arash Rezazadeh Kalebasty> ;Nature Reviews. Urology. 2023 Sep 1
• 4 citations
  Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment.
  Kyle Nolla, David J Benjamin, David Cella> ;Nature Reviews. Urology. 2023 Jul 1
• 4 citations
  Modernising the US FDA's Accelerated Approval pathway.
  David J Benjamin, Mark P Lythgoe> ;The Lancet. Oncology. 2023 Mar 1
• Nivolumab plus cabozantinib for advanced renal cell carcinoma.
  David J Benjamin, Kyle Nolla, David Cella> ;Future Oncology. 2022 Dec 1
• Join now to see all

Abstracts/Posters

• Comprehensive Analysis of Targetable Alterations in Urachal Cancer by NGS
  Benjamin DJ, Adeyelu TT, Darabi S, Lee T, McKay RR, Oberley MK, Rezazadeh A, Elliott A, ASCO Genitourinary Cancers Symposium, San Francisco, CA, 1/26/2024
• Testicular cancer: Trends in incidence and demographics from 23,214 cases in California from 2000-2020
  D.J. Benjamin, A. Shrestha, D. Fellman, A. Rezazadeh Kalebasty, ESMO Congress 2023, Madrid, Spain, 10/23/2023
• Characterization and survival benefit of drugs approved for advanced renal cell carcinoma
  David Joseph Benjamin, Arash Rezazadeh, ASCO Genitourinary Cancers Symposium, San Francisco, CA, 2/18/2023
• Characterization and survival benefit of drugs approved for metastatic prostate cancer
  David Joseph Benjamin, Arash Rezazadeh, ASCO Genitourinary Cancers Symposium, San Francisco, CA, 2/17/2023
• Urachal cancer: A population-based study of 315 cases in California from 1988-2019
  David J Benjamin, Anshu Shrestha, Dimitra Fellman, Rosemary Cress, Arash Rezazadeh Kalebasty, ESMO Congress 2022, Paris, France, 9/12/2022
• Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study of 15,435 cases from the California Cancer Registry (2009-2018).
  David Joseph Benjamin, Dimitra Fellman, Anshu Shrestha, Arash Rezazadeh, ASCO Genitourinary Cancers Symposium, 1/17/2022
• The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospect...
  Karen Kelly, Shuai Chen, Joanna B Eldredge, David Joseph Benjamin, Matthew C Mulroy, Nadeem Tabbara, John Sharp, Jonathan Wade Goldman, Matthew A. Gubens, Jeremy P. Ha..., 2021 ASCO Annual Meeting, 6/4/2021
• Retrospective Analysis of Adults with Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
  Tenold M, Moskoff B, Benjamin D, Jonas BA, 60th Annual American Society of Hematology Meeting and Exposition, San Diego, CA, 11/29/2018
• Efficacy of Single-Agent Pemetrexed in Platinum Refractory Metastatic Urothelial Cancer
  Benjamin DJ, Bambury RM, Chaim JL, Zabor EC, Ostrovnaya I, Garcia-Grossman IR, Iyer G, Bajorin DF, and Rosenberg JE, ASCO Genitourinary Cancers Symposium, San Francisco, CA, 1/31/2014
• Join now to see all

Lectures

• A Population-Based Study of Incidence and Survival Trends of 1,588 Thymic Malignancies (TM): Results from the California Cancer Registry (CCR) 
  IASLC 19th World Conference on Lung Cancer, Toronto, Canada - 9/25/2018